Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Treasury Shares (2017 - 2025)

Arcus Biosciences has reported Treasury Shares over the past 9 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.9 million for Q4 2025, up 31.82% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (up 31.82% YoY), and the annual figure for FY2025 was $2.9 million, up 31.82%.
  • Treasury Shares for Q4 2025 was $2.9 million at Arcus Biosciences, up from $2.2 million in the prior quarter.
  • Over the last five years, Treasury Shares for RCUS hit a ceiling of $2.9 million in Q4 2025 and a floor of $1.1 million in Q4 2021.
  • Median Treasury Shares over the past 5 years was $1.5 million (2023), compared with a mean of $1.8 million.
  • Biggest five-year swings in Treasury Shares: surged 48.92% in 2021 and later grew 15.38% in 2023.
  • Arcus Biosciences' Treasury Shares stood at $1.1 million in 2021, then rose by 18.18% to $1.3 million in 2022, then increased by 15.38% to $1.5 million in 2023, then soared by 46.67% to $2.2 million in 2024, then surged by 31.82% to $2.9 million in 2025.
  • The last three reported values for Treasury Shares were $2.9 million (Q4 2025), $2.2 million (Q4 2024), and $1.5 million (Q4 2023) per Business Quant data.